- Home
- Equipment
- usa massachusetts
- hematopoietic stem
Refine by
Hematopoietic Stem Equipment Supplied In Usa Massachusetts
6 equipment items found
Manufactured by:Sana Biotechnology based inSeattle, WASHINGTON (USA)
Hemoglobinopathies: Sickle cell disease, ...
Manufactured by:Editas Medicine based inCambridge, MASSACHUSETTS (USA)
We are pursuing a number of diseases using an in vivo editing approach, focusing on hematopoietic stem cells and other tissue types, and we are excited about the progress we’ve ...
by:Vor Biopharma based inCambridge, MASSACHUSETTS (USA)
Knocking out CD33 and CLL-1 through gene editing offers a promising new approach to treating patients with AML using our novel eHSC platform. Our research demonstrates that multiplex genome editing of allogeneic hematopoietic stem cells may represent another exciting strategy to efficiently and safely edit multiple genes in blood stem cells, ...
Manufactured by:Seres Therapeutics, Inc. based inCambridge, MASSACHUSETTS (USA)
SER-155 is an investigational, oral, rationally designed, fermented microbiome therapeutic designed to reduce the incidence of gastrointestinal infections, bacteremia, and graft versus host disease (GvHD) in immunocompromised patients, including patients receiving allogeneic hematopoietic stem cell transplantation ...
Manufactured by:Editas Medicine based inCambridge, MASSACHUSETTS (USA)
EDIT-301 is an experimental cell therapy medicine under investigation for the treatment of severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). EDIT-301 consists of patient-derived CD34+ hematopoietic stem and progenitor cells edited at the gamma globin gene (HBG1 and HBG2) promoters, where naturally occurring fetal hemoglobin (HbF) ...
by:Intellia Therapeutics, Inc. based inCambridge, MASSACHUSETTS (USA)
We plan to initiate patient screening for a first-in-human Phase 1 study of NTLA-5001, a WT1-directed TCR T cell therapy for the treatment of AML, by the end of 2021. Our first ex vivo development candidate seeks to treat acute myeloid leukemia (AML) by engineering autologous T cell receptors (TCR) directed towards the Wilms’ Tumor 1 (WT1) antigen, an over-expressed protein that is often ...